Induction of antigen spread after sipuleucel-T treatment and its association with improved clinical outcome by Debraj GuhaThakurta et al.
POSTER PRESENTATION Open Access
Induction of antigen spread after sipuleucel-T
treatment and its association with improved
clinical outcome
Debraj GuhaThakurta*, Li-Qun Fan, Tuyen Vu, Nadeem A Sheikh, James B Trager
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Introduction
An effective cancer immunotherapy that triggers immune-
mediated lysis of tumor cells, may lead to the priming of T
or B lymphocytes against tumor antigens distinct from the
initial target/s of the therapy. This is referred to as antigen
or epitope spread. Evidence of antigen spread after treat-
ment may not only provide insights into the mechanism
of action (MoA) of cancer immunotherapies, but also pro-
vide pharmacodynamic (post-treatment) biomarkers of
clinical response and outcome. Sipuleucel-T, an FDA
approved autologous cellular immunotherapy for the
treatment of symptomatic or minimally symptomatic,
metastatic castrate-resistant prostate cancer (mCRPC), is
designed to elicit immune responses to the prostate-speci-
fic antigen, Prostatic Acid Phosphatase (PAP). We sought
to determine if antigen spread occurs in response to sipu-
leucel-T treatment.
Study & methods
Using protein microarrays (ProtoArrays®), followed by
independent technical validation using Luminex, we evalu-
ated humoral antigen spread after sipuleucel-T treatment
in IMPACT, a controlled phase 3 clinical study, where
sipuleucel-T has shown to improve overall survival (OS)
in mCRPC patients (N Engl J Med, 2010, 363, p. 411). We
have also assessed antigen spread in an independent clini-
cal study and evaluated the association of antigen spread
with OS in sipuleucel-T treated subjects.
Results
Subjects in the sipuleucel-T arm of IMPACT showed sig-
nificant IgG responses on the ProtoArray against targets
aberrantly expressed in prostate tumors and targets in
pathways involved in prostate cancer progression (includ-
ing known oncogenes). Control arm subjects did not
show significant IgG responses on the ProtoArray.
IgG responses to specific antigens identified using the
ProtoArray in the sipuleucel-T treated subjects were sub-
sequently validated using Luminex xMAP. This con-
firmed that the sipuleucel-T treated subjects consistently
mounted elevated IgG responses against multiple cancer
antigens (other than PAP) after treatment (> 25% sub-
jects showing ≥ 3 fold increase in IgG levels), whereas
control subjects did not (≤ 5% subjects showing ≥ 3 fold
increase in IgG levels). The IgG responses identified from
IMPACT were observed in an independent sipuleucel-T
phase 2 clinical study (ProACT, NCT00715078). Addi-
tionally, humoral antigen spread was observed to be
significantly associated with improved OS in IMPACT.
Conclusions
This study provides further insight into the MoA of sipu-
leucel-T, and may assist in the identification of post-
treatment biomarkers of clinical outcome. The methods
and results presented here may also benefit the deve-
lopment of pharmacodynamic biomarkers of clinical
outcome for other cancer immunotherapies.
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